On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.
FDA will select an initial cohort of new pharmaceutical facilities and begin conducting PreCheck activities in 2026. A new manufacturing facility is one that is no...
Continue Reading
Sign up for FREE to read the full article and access 130K+ alternative investment headlines.